The global automated microbiology market size was valued at USD 8.37 billion in 2025 and is projected to grow from USD 9.21 billion in 2026 to USD 19.85 billion by 2034, registering a CAGR of 10.07% during the forecast period from 2026 to 2034. North America dominated the automated microbiology market with a market share of 38.6% in 2025.
Advances in automated microbiology are shifting laboratory diagnostics from manual, reactive testing to faster, standardized, and data-driven workflows, with total laboratory automation systems reducing turnaround time by up to 40-60% in clinical settings. The rising burden of infectious diseases and antimicrobial resistance, which contributes to nearly 4.95 million deaths annually worldwide, drives demand for rapid identification and antimicrobial susceptibility testing solutions. Growing test volumes across hospitals, pharmaceutical quality control, and food safety sectors support the adoption of automated culture systems, molecular diagnostics, and digital imaging platforms.
Download a Free Sample To learn more about this report,
Integration of Robotics in Microbiology Laboratory Workflows
The Automated Microbiology Market analysis shows that laboratories handle repetitive activities such as specimen transport, plate handling, incubation, and imaging, which encourages the integration of robotic automation into microbiology workflows. This transition is reducing manual handling and standardizing routine processes, resulting in higher laboratory throughput and more consistent processing of microbiology specimens. For example, BD’s Kiestra Total Lab Automation system automates plate labeling, inoculation, transportation, incubation, imaging, culture reading, and result reporting, while its configuration can accommodate up to 6,912 plates.
Development of Automated Sample Preparation and Processing Systems
The need for consistent specimen preparation and faster processing is encouraging laboratories to adopt automated systems for sample identification, inoculation, streaking, and preparation for downstream microbial testing. This transition is reducing manual preparation steps and improving reproducibility, with BD reporting that its InoqulA sample processor can reduce the need for subcultures by up to 73% depending on the streaking pattern. For example, the system supports automated processing of both liquid and non-liquid samples and uses standardized inoculation and streaking to produce more consistent cultures.
Skilled Personnel Shortage and Faster Pathogen Identification Drive Market
The shortage of skilled healthcare personnel creates a need for automated microbiology systems that can help laboratories handle testing workloads with available staff. WHO projects a global health workforce shortage of 11 million workers by 2030, highlighting staffing pressure across healthcare systems. For example, automated microbiology systems can standardize routine identification and susceptibility testing, allowing laboratory specialists to focus on complex cases and result interpretation. This workforce constraint supports adoption of automated instruments that improve staff utilization and laboratory capacity.
The need for timely pathogen identification creates demand for microbiology systems that provide diagnostic information quickly and support appropriate treatment decisions. WHO highlights the need to improve the “precision, speed, and usability” of diagnostic tools for antimicrobial resistance. For example, automated identification and antimicrobial susceptibility systems can help laboratories identify bacterial pathogens and determine their response to antibiotics. This clinical requirement supports adoption of automated microbiology platforms across hospitals, diagnostic laboratories, and reference testing centers.
System Integration and Maintenance Requirements Restrain Market Expansion
Complex integration with existing laboratory systems can create compatibility issues between automated microbiology instruments, laboratory information systems, and established workflows. These challenges can require additional software, interfaces, validation, and technical support, increasing deployment time and implementation costs. The added integration burden can discourage laboratories from upgrading and slow the adoption of automated microbiology technologies.
High maintenance and service requirements arise from the need for calibration, preventive maintenance, software updates, and technical support for automated microbiology systems. These ongoing requirements increase operating costs and can create downtime when specialized servicing or replacement parts are needed. The higher maintenance burden can discourage investment among smaller laboratories and limit market growth.
Cloud-Based Data Management and Antimicrobial Susceptibility Testing Offers Growth Opportunities
Microbiology laboratories, diagnostic networks, and laboratory software providers can connect instruments with cloud platforms for result storage, reporting, quality tracking, and remote access. Thermo Fisher Scientific’s Platform for Science runs on AWS and supports secure data access, sharing, and collaboration across laboratories, creating recurring revenue through software subscriptions and data-management services. Such digital capabilities can support market growth.
Diagnostic laboratories, hospitals, and microbiology equipment manufacturers can use automated systems to assess pathogen responses to antimicrobial drugs. bioMérieux’s VITEK 2 can provide routine AST results in 6–8 hours, while VITEK REVEAL can deliver AST results in as little as 3 hours for certain applications, creating revenue through instruments, testing cards, and service contracts. Such faster testing capabilities can support market growth.
Capital Investment and Data Security Hinders Growth
Automated microbiology workflows require substantial investment in instruments, robotics, consumables, and laboratory infrastructure. WHO notes that access to appropriate and affordable health technologies remains a challenge, particularly in low-resource settings where healthcare infrastructure and investment capacity are constrained. High upfront expenditure can therefore restrict adoption among smaller laboratories and healthcare facilities, limiting market penetration and slowing expansion into underserved markets.
Automated microbiology platforms increasingly generate and transfer sensitive patient and diagnostic data through connected laboratory and healthcare systems. HHS reported more than 630 ransomware incidents affecting healthcare worldwide in 2023, including more than 460 incidents in the U.S. health sector, demonstrating the operational and security risks associated with increasingly connected healthcare environments. These risks can increase cybersecurity investment and compliance requirements, making healthcare organizations more cautious about adopting connected laboratory automation.
The instruments segment accounted for a share of 55.8% in 2025, owing to the widespread use of automated microbiology instruments for microbial identification, blood culture analysis, colony counting, sample preparation, and antibiotic susceptibility testing. the increasing demand for rapid, accurate, and automated laboratory workflows further strengthens the segment’s dominant position in the automated microbiology market.
The software segment is expected to grow at a CAGR of 10.38% during the forecast period, driven by increasing adoption of digital laboratory workflows, integration of data management and automation technologies, and growing demand for real-time analysis and efficient microbiology laboratory operations. the automated microbial identification systems segment supports rapid and accurate identification of microorganisms, while the automated blood culture systems segment enables faster detection of bloodstream infections. the automated colony counters segment improves counting efficiency and reduces manual errors, while the automated sample preparation systems segment supports standardized and efficient laboratory workflows. the automated antibiotic susceptibility testing (AST) systems segment facilitates rapid antimicrobial susceptibility analysis, while other instruments support additional automated microbiology applications. the reagents & kits segment provides essential materials for microbial testing and analysis, with culture media supporting microorganism growth, stains & dyes enabling microscopic visualization, and assay kits & panels supporting targeted microbial detection and analysis. other reagents & kits contribute to specialized testing requirements across microbiology laboratories.
Request Customizationto receive a tailored report.
The clinical diagnostics segment accounted for a share of 43.8% in 2025 due to the widespread use of automated microbiology technologies for rapid pathogen identification, infection diagnosis, and antimicrobial susceptibility testing. the growing demand for accurate and efficient diagnostic workflows, rising healthcare-associated infections, and increasing laboratory automation further strengthen the segment’s dominant position in the automated microbiology market.
The biopharmaceutical production segment is expected to grow at a CAGR of 9.21% during the forecast period, fueled by increasing demand for automated microbial testing in drug development, biologics manufacturing, quality control, and contamination monitoring. the environmental & water testing segment supports microbial analysis of water and environmental samples, while the food & beverage testing segment enables detection of microorganisms and contamination to maintain product safety and quality. the other applications segment includes additional microbiological testing requirements across specialized laboratory and industrial settings.
The hospitals & diagnostic laboratories segment accounted for a share of 48.9% in 2025, supported by the widespread use of automated microbiology technologies for clinical diagnosis, pathogen identification, infection detection, and antimicrobial susceptibility testing. the increasing demand for rapid and accurate diagnostic workflows and growing laboratory automation further strengthen the segment’s dominant position in the automated microbiology market.
The pharmaceutical & biotechnology companies segment is expected to grow at a CAGR of 9.37% during the forecast period, propelled by increasing demand for automated microbial testing in drug development, biopharmaceutical manufacturing, quality control, and contamination monitoring. the academic & research institutes segment supports microbiological research, experimental studies, and development of advanced diagnostic and testing methods, while the other end user segment includes additional healthcare, industrial, and laboratory settings adopting automated microbiology technologies.
Speak to an Analystto discuss market opportunities.
The North America automated microbiology market accounted for the largest regional share of 38.6% in 2025, driven by advanced laboratory infrastructure, increasing adoption of automated diagnostic technologies, and rising demand for rapid microbiological testing. The U.S. automated microbiology market is supported by the U.S. Centers for Disease Control and Prevention’s Advanced Molecular Detection program, which integrates genomic sequencing, bioinformatics, and other advanced laboratory technologies to improve pathogen detection and outbreak response, supporting demand for automated microbiology systems across clinical and public health laboratories.
The Canada automated microbiology market is supported by the Public Health Agency of Canada’s National Microbiology Laboratory, which is expanding laboratory-based infectious disease surveillance and adopting modern technologies for pathogen detection and characterization. In addition, Canada’s Antimicrobial Resistance Network collects antimicrobial susceptibility testing data from clinical and veterinary laboratories across multiple provinces and territories, supporting continued demand for advanced and automated microbiology testing capabilities.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific automated microbiology market is expected to grow at a CAGR of 10.26%, showcasing the fastest-growing regional market, supported by expanding healthcare infrastructure, increasing investments in laboratory automation, and rising adoption of automated microbiology solutions. In Japan, the Ministry of Health, Labour and Welfare published the 4th edition of its Laboratory Biosafety Manual in August 2026, alongside updated pathogen-management guidance. The continued strengthening of laboratory biosafety and microbiological testing practices supports the modernization of clinical microbiology laboratories and adoption of advanced laboratory technologies.
In China, the National Health Commission issued new 2026 clinical microbiology laboratory standards, including standards for specimen collection and transport, blood-culture procedures, infectious-disease diagnostic testing, and invasive fungal disease testing, with implementation scheduled for November 1, 2026. These standards support standardized and higher-quality microbiological testing across clinical laboratories. In South Korea, the Korea Disease Control and Prevention Agency operates a national infectious-disease diagnostic testing system connecting public institutions, hospitals, clinics, and contract testing laboratories, with standardized testing methods, pathogen identification, laboratory quality management, and proficiency evaluation, supporting continued modernization of microbiology testing infrastructure. In India, the Indian Council of Medical Research maintains standardized bacteriology and mycology laboratory procedures, including its Standard Operating Procedures for Bacteriology and Mycology Laboratories, while in 2026 it issued an expression of interest for technology transfer covering new diagnostic technologies, including a CRISPR-Cas12a-based assay for detecting Burkholderia pseudomallei, supporting the development and modernization of microbiological diagnostics.
The Europe automated microbiology market accounted for a regional share of 29.4% in 2025, supported by established laboratory systems, increasing demand for efficient diagnostic workflows, and growing adoption of automated microbiology technologies. In the U.K. automated microbiology market, NHS Lothian issued a 2026 procurement for a next-generation automated laboratory solution for microbiology services at the Royal Infirmary of Edinburgh, with an estimated contract value of £3 million. The managed service includes integrated IT, major analysers, reagents, and consumables for the majority of the microbiology testing repertoire, indicating institutional investment in laboratory automation.
In the Germany automated microbiology market, the Robert Koch Institute reported that 126 laboratories contributed data to the nationwide Antibiotic Resistance Surveillance (ARS) system in 2025, while 593 hospitals participated in antibiotic-consumption surveillance. The RKI also maintains 21 National Reference Centres and 38 Consultant Laboratories for infectious-disease surveillance, diagnostics, and antimicrobial-resistance monitoring for the 2026–2028 period, supporting continued demand for advanced microbiology testing capabilities. Meanwhile, the France automated microbiology market is supported by the Ministry of Health's updated 2024–2034 national roadmap for antimicrobial resistance, which includes increased support for research and innovation and strengthened surveillance. The strategy contains 17 objectives aimed at improving antimicrobial-resistance prevention, monitoring, and response, supporting the need for faster and more standardized microbiological testing and diagnostic technologies.
The UAE automated microbiology market is expected to benefit from the increasing adoption of automated laboratory technologies, with Dubai Municipality introducing advanced automated testing technology in August 2026 that reduced oil and fat testing time from two hours to two minutes and increased daily testing capacity by 900%, from six to 60 samples, demonstrating the UAE’s continued investment in faster and more automated laboratory testing capabilities.
The Africa automated microbiology market is expected to benefit from continued investments in laboratory and antimicrobial-resistance surveillance capacity, with WHO reporting in 2026 that Tanzania is expanding access to advanced laboratory technology for genomic AMR surveillance and pathogen detection, while WHO’s regional strategy for 2023–2032 calls for expanded availability and accessibility of quality-assured diagnostic and laboratory services across African health systems.
The automated microbiology market is moderately consolidated, with diagnostic equipment manufacturers, clinical laboratory technology companies, microbiology testing solution providers, life sciences companies, laboratory automation specialists, and regional diagnostic technology suppliers competing across clinical diagnostics, pharmaceutical testing, food safety, environmental testing, and research applications. Established players compete primarily on automation capabilities, testing accuracy, workflow efficiency, instrument reliability, throughput, software integration, regulatory compliance, product portfolios, technical support, and global distribution networks, with leading players such as bioMérieux, Thermo Fisher Scientific, Danaher Corporation, Abbott Laboratories, and Becton, Dickinson and Company estimated to account for approximately 50% of the global market based on their microbiology portfolios, automation capabilities, diagnostic technologies, geographic presence, and competitive positioning.
Emerging and regional players within the automated microbiology market ecosystem compete through cost-effective systems, compact and flexible platforms, specialized testing solutions, simplified workflows, customized configurations, localized support, rapid product development, and integration of advanced technologies to address specific laboratory requirements and strengthen their market presence. These players also focus on developing application-specific automation solutions, improving workflow efficiency, and offering flexible configurations to expand their customer base and market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Genome Editing Market Size, Share, Growth, Analysis, Report, 2034
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com